scholarly journals Incidence and predictors of venous thromboembolism after surgery for gynecologic cancer

2021 ◽  
Vol 42 (3) ◽  
pp. 477
Keyword(s):  
Venous Thromboembolism ◽  
Gynecologic Cancer

Patient cost associated with filling a prescription for extended-duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer

2012 ◽  
Vol 127 (1) ◽  
pp. 18-21 ◽  
Author(s):  
Katherine Cain ◽  
Kathleen M. Schmeler ◽  
Ginger Langley ◽  
Oliver Max ◽  
Pedro T. Ramirez ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Gynecologic Cancer ◽  
Patient Cost ◽  
Vte Prophylaxis ◽  
Extended Duration

Patient costs associated with extended-duration venous thromboembolism (VTE) prophylaxis following surgery for gynecologic cancer

2012 ◽  
Vol 125 ◽  
pp. S15
Author(s):  
K. Cain ◽  
G. Langley ◽  
O. Max ◽  
P. Ramirez ◽  
C. Levenback ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Gynecologic Cancer ◽  
Vte Prophylaxis ◽  
Patient Costs ◽  
Extended Duration

Retrospective Indication-Matched Cohort Study of Reference Product and Biosimilar: Bevacizumab Versus Bevacizumab-Awwb

2021 ◽  
pp. 001857872110468
Author(s):  
Jennifer Philippon Booth ◽  
Jeffrey Pilz
Keyword(s):  
Cohort Study ◽  
Venous Thromboembolism ◽  
Adverse Drug Events ◽  
Gynecologic Cancer ◽  
Matched Cohort ◽  
Matched Cohort Study ◽  
Gastrointestinal Bleed ◽  
Post Marketing Surveillance ◽  
Wide Range ◽  
Grade 3

Introduction: Due to the abbreviated approval pathway and extrapolation to non-studied indications, an increased importance is placed on post-marketing surveillance of biosimilars to supplement existing evidence and enhance patient and provider confidence. Bevacizumab-awwb (ABP 215, Mvasi) was the first biosimilar approved to bevacizumab (Avastin), a recombinant humanized monoclonal IgG1 antibody that inhibits the vascular endothelial growth factor (VEGF). Purpose: To evaluate utilization, safety, and financial outcomes of bevacizumab-awwb compared to bevacizumab at a national cancer institute (NCI)-designated cancer center. Methods: A single center, retrospective, 1:1 indication-matched cohort study of adult patients who received bevacizumab or bevacizumab-awwb between October 1, 2019 and October 1, 2020 was performed. Thirty-four patients received bevacizumab-awwb during the study period and were matched by indication to 34 randomly selected patients who received bevacizumab. Indications for both groups included: colorectal cancer (n = 19), gynecologic cancer (n = 10), glioblastoma (n = 3), hepatocellular carcinoma (n = 1), and lung cancer (n = 1). Results: Baseline and medication utilization characteristics were similar for this indication-matched cohort of 68 patients receiving bevacizumab-awwb or bevacizumab. Patients in the bevacizumab group had a higher proportion of public payer coverage (64.7% vs 38.2%, P = .029). A higher proportion of patients in the bevacizumab-awwb group remained on active treatment at the end of the study period (52.9%) as compared to the bevacizumab group (35.3%); however, differences in final treatment status and reasons for discontinuation were not statistically significant ( P = .218). Rates of worsened hypertension (44.1% vs 44.1%) and worsened proteinuria (38.2% vs 23.5%, P = .077) were common in both groups. Grade 3 adverse drug events in the bevacizumab group included: gastrointestinal perforation (n = 1), gastrointestinal bleed (n = 1), hypertension (n = 2), and venous thromboembolism (n = 2). Grade 3 adverse drug events in the bevacizumab-awwb group included: epistaxis (n = 1), gastrointestinal bleed (n = 1), hypertension (n = 1), intracerebral hemorrhage (n = 1), venous thromboembolism (n = 3), and arterial thromboembolism (n = 1). One patient in the bevacizumab-awwb group experienced grade 4 hypertension. Median drug cost per dose and per milligram for bevacizumab-awwb was less than bevacizumab, representing a 15.8% and 12.1% discount, respectively. Conclusion: Utilization and safety outcomes were similar for this indication-matched cohort of 68 patients receiving bevacizumab or bevacizumab-awwb across a wide range of disease states.

The clinical utility of the Khorana score in determining risk for venous thromboembolism in patients with gynecologic cancer

2021 ◽  
Vol 162 ◽  
pp. S288-S289
Author(s):  
Annie Apple ◽  
Lauren Prescott ◽  
Marc Robinson ◽  
Kendall Shultes ◽  
Alaina Brown
Keyword(s):  
Venous Thromboembolism ◽  
Clinical Utility ◽  
Gynecologic Cancer

scholarly journals Venous thromboembolism in cancer patients: report of baseline data from the multicentre, prospective Cancer-VTE Registry

2020 ◽  
Vol 50 (11) ◽  
pp. 1246-1253
Author(s):  
Yasuo Ohashi ◽  
Masataka Ikeda ◽  
Hideo Kunitoh ◽  
Mitsuru Sasako ◽  
Takuji Okusaka ◽  
...  
Keyword(s):  
Risk Factor ◽  
Deep Vein Thrombosis ◽  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Clinical Care ◽  
Gynecologic Cancer ◽  
Cancer Type ◽  
Cancer Stage ◽  
Vein Thrombosis ◽  
Deep Vein

Abstract Background The Cancer-VTE Registry evaluates the occurrence and management of venous thromboembolism in Japanese participants with major solid tumors. Using Registry data, we evaluated the frequency of concurrent venous thromboembolism in cancer patients prior to treatment initiation by cancer type. Methods The Cancer-VTE Registry is an ongoing (March 2017–September 2020) prospective cohort study using a nationwide, multicentre clinical registry. Participants aged ≥20 years with colorectal, lung, stomach, pancreatic, breast or gynecologic cancer, confirmed staging, ≥6 months life expectancy post-registration and who had undergone venous thromboembolism screening were managed with routine clinical care. Venous thromboembolism frequency at registration was evaluated. Results Of 9735 participants, 571 (5.9%) had venous thromboembolism at baseline, including asymptomatic [5.5% (n = 540)] and symptomatic venous thromboembolism [0.3% (n = 31)]. Most participants with venous thromboembolism (n = 506, 5.2%) had deep vein thrombosis only; 65 (0.7%) had pulmonary embolism with/without deep vein thrombosis. The prevalence of distal and proximal deep vein thrombosis was 4.8% (n = 466) and 0.9% (n = 83), respectively. The highest prevalence of venous thromboembolism was for pancreatic cancer (8.5%) and the lowest for breast cancer (2.0%). Venous thromboembolism prevalence increased as cancer stage advanced. Conclusions Although there was a marked difference in venous thromboembolism by cancer type, the data suggest that cancer stage is an important risk factor for venous thromboembolism. Thus, metastasis seems a critical risk factor for venous thromboembolism. This is the first demonstration of venous thromboembolism prevalence and risk factors in Japanese cancer patients prior to treatment. Trial registration UMIN000024942.

Incidence and factors associated with venous thromboembolism in women with gynecologic cancer

2020 ◽  
Vol 185 ◽  
pp. 49-54 ◽  
Author(s):  
Ingrid de Araujo Trugilho ◽  
Marcos José Pereira Renni ◽  
Giselle Coutinho Medeiros ◽  
Luiz Claudio Santos Thuler ◽  
Anke Bergmann
Keyword(s):  
Venous Thromboembolism ◽  
Gynecologic Cancer ◽  
Factors Associated

Venous thromboembolism prevention in gynecologic cancer surgery: A systematic review

2007 ◽  
Vol 105 (3) ◽  
pp. 813-819 ◽  
Author(s):  
M. Heather Einstein ◽  
Elizabeth A. Pritts ◽  
Ellen M. Hartenbach
Keyword(s):  
Systematic Review ◽  
Venous Thromboembolism ◽  
Gynecologic Cancer ◽  
Cancer Surgery ◽  
Venous Thromboembolism Prevention

A Protocol of Dual Prophylaxis for Venous Thromboembolism Prevention in Gynecologic Cancer Patients

2008 ◽  
Vol 112 (5) ◽  
pp. 1091-1097 ◽  
Author(s):  
M Heather Einstein ◽  
David M. Kushner ◽  
Joseph P. Connor ◽  
Alex A. Bohl ◽  
Thomas J. Best ◽  
...  
Keyword(s):  
Venous Thromboembolism ◽  
Cancer Patients ◽  
Gynecologic Cancer ◽  
Venous Thromboembolism Prevention
Sign in / Sign up

Export Citation Format

Share Document